The German company Curevac decided to withdraw an application for approval of his vaccine in the European Union. Perhaps this happened due to the low efficacy of the drug – it was only 47 percent, Reuters writes.
The company itself does not disclose the reasons why I decided to withdraw the application. Now she will work on a vaccine together with the British company GlaxosmithKline.
Treaty on preliminary procurement of doses of the CureVac vaccine, signed between the German company and EU countries, will expire.
In early August, British scientists declared the fall in the effectiveness of vaccine against coronavirus infection. According to experts that exist at the current moment of vaccine against the usual variants of the coronavirus show low efficiency against the “Delta” -Tamma. They expressed the opinion that the virus is actively spreading not only among the unmaded, but also among those who have already passed vaccination.